Cargando…

Therapy-related Myeloid Neoplasms: Considerations for Patients’ Clinical Evaluation

Therapy-related myeloid neoplasms (t-MNs) encompass a specific sub-group of myeloid malignancies arising after exposure to radio/cytotoxic agents for the treatment of unrelated diseases. Such malignancies present unique features, including advanced age, high comorbidities burden, and unfavorable gen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palmieri, Raffaele, Paterno, Giovangiacinto, Mallegni, Flavia, Frenza, Federica, De Bernardis, Ilenia, Moretti, Federico, Meddi, Elisa, Del Principe, Maria Ilaria, Maurillo, Luca, Venditti, Adriano, Buccisano, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Università Cattolica del Sacro Cuore 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497317/ https://www.ncbi.nlm.nih.gov/pubmed/37705524 http://dx.doi.org/10.4084/MJHID.2023.051

Ejemplares similares

Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML
por: Meddi, Elisa, et al.
Publicado: (2023)

Time for Dynamic Assessment of Fitness in Acute Myeloid Leukemia
por: Palmieri, Raffaele, et al.
Publicado: (2022)

Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness
por: Palmieri, Raffaele, et al.
Publicado: (2020)

Predictors of Early Thrombotic Events in Adult Patients with Acute Myeloid Leukemia: A Real-World Experience
por: Paterno, Giovangiacinto, et al.
Publicado: (2022)

Pulmonary function testing for fitness assessment in asymptomatic adults with newly diagnosed acute myeloid leukemia
por: Palmieri, Raffaele, et al.
Publicado: (2022)

PB1835: THE ISTH-DIC SCORE PREDICTS 30-DAYS OUTCOME IN NON-M3 ACUTE MYELOID LEUKEMIA PATIENTS
por: Paterno, G., et al.
Publicado: (2022)

In BCR-ABL1 Positive B-Cell Acute Lymphoblastic Leukemia, Steroid Therapy Induces Hypofibrinogenemia
por: Buzzatti, Elisa, et al.
Publicado: (2022)

Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial
por: Buccisano, Francesco, et al.
Publicado: (2022)

Fever of Unknown Origin and Multidrug Resistant Organism Colonization in AML Patients
por: Guarnera, Luca, et al.
Publicado: (2023)

Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation
por: Buccisano, Francesco, et al.
Publicado: (2021)

Case report: A Saprochaete clavata (Magnusiomyces clavatus) severe infection effectively treated with granulocyte transfusion in a young patient with myeloid sarcoma
por: Pasqualone, Gianmario, et al.
Publicado: (2022)

Diagnostic Performance and Safety of Bronchoalveolar Lavage in Thrombocytopenic Haematological Patients for Invasive Fungal Infections Diagnosis: A Monocentric, Retrospective Experience
por: Cefalo, Mariagiovanna, et al.
Publicado: (2019)

Treatment of Acute Myeloid Leukemia with 20–30% Bone Marrow Blasts
por: Maurillo, Luca, et al.
Publicado: (2013)

Real-life experience of secondary prophylaxis with DOACs in splanchnic venous thrombosis during COVID-19 pandemic
por: Guarnera, Luca, et al.
Publicado: (2023)

Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications
por: Del Principe, Maria Ilaria, et al.
Publicado: (2016)

NK Cell Inflammation in the Clinical Outcome of Colorectal Carcinoma
por: Coppola, Andrea, et al.
Publicado: (2015)

ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol
por: Buccisano, Francesco, et al.
Publicado: (2022)

Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy
por: Sarlo, Chiara, et al.
Publicado: (2013)

Can Polycythemia Vera Evolve from Acute Myeloid Leukemia? Report of a Case Showing a Simultaneous Minor JAK2 V617F Mutated Clone
por: Borsellino, Beatrice, et al.
Publicado: (2022)

FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance
por: Caratelli, Sara, et al.
Publicado: (2017)

Impairment of FOXM1 expression in mesenchymal cells from patients with myeloid neoplasms, de novo and therapy-related, may compromise their ability to support hematopoiesis
por: Falconi, Giulia, et al.
Publicado: (2022)

The Venetoclax/Azacitidine Combination Targets the Disease Clone in Acute Myeloid Leukemia, Being Effective and Safe in a Patient with COVID-19
por: Cristiano, Antonio, et al.
Publicado: (2022)

Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia
por: Buccisano, Francesco, et al.
Publicado: (2018)

MRD in AML: The Role of New Techniques
por: Voso, Maria Teresa, et al.
Publicado: (2019)

Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia
por: Aureli, Anna, et al.
Publicado: (2021)

P432: VALIDATION OF LIMIT OF QUANTIFICATION APPROACH BASED FLOW CYTOMETRY FOR MEASURABLE RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA IN THE HOVON-SAKK-132 TRIAL
por: Tettero, Jesse, et al.
Publicado: (2023)

Treatment of Low-Blast Count AML using Hypomethylating Agents
por: De Bellis, Eleonora, et al.
Publicado: (2017)

Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage
por: Arriga, Roberto, et al.
Publicado: (2015)

Characterization of FLT3-ITD(mut) acute myeloid leukemia: molecular profiling of leukemic precursor cells
por: Travaglini, Serena, et al.
Publicado: (2020)

P505: GIMEMA AML1819 TRIAL: GEMTUZUMAB OZOGAMICIN PLUS INTENSIVE CHEMOTHERAPY IMPACTS ON THE LEVEL OF POST-CONSOLIDATION MEASURABLE RESIDUAL DISEASE (MRD) IN ACUTE MYELOID LEUKEMIA
por: Venditti, Adriano, et al.
Publicado: (2023)

Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy
por: Del Principe, Maria Ilaria, et al.
Publicado: (2014)

The effect of COVID-19 on the frequency of Pneumocystis jirovecii pneumonia: a monocentric, retrospective, and observational study
por: Del Prete, Valentina, et al.
Publicado: (2023)

Editorial: Measurable residual disease in hematologic malignancies
por: Buccisano, Francesco, et al.
Publicado: (2023)

Clinical significance of occult central nervous system disease in adult acute lymphoblastic leukemia: a multicenter report from the Campus ALL Network
por: Del Principe, Maria Ilaria, et al.
Publicado: (2019)

Co-occurrence of myeloid neoplasm and plasma cell neoplasm
por: Jum’ah, Husam, et al.
Publicado: (2022)

Extracellular Vesicles in Myeloid Neoplasms
por: Karantanou, Christina, et al.
Publicado: (2022)

International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms
por: Gianelli, Umberto, et al.
Publicado: (2022)

Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease
por: Maurillo, Luca, et al.
Publicado: (2019)

Myeloid Neoplasms in the Guise of Nutritional Deficiency
por: Parthasarathy, Veda
Publicado: (2012)

Pegylated liposomal doxorubicin for myeloid neoplasms
por: Zhang, Cheng, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hok7blfn7kuoq7hvtuaqp9cr8h